Health authorities in the UK have moved to rename polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, alongside introducing recommendations for annual health reviews to better support affected women. The condition impacts approximately one in eight women in the UK and can affect hair growth, menstrual patterns, fertility and mood.
Two women diagnosed with the condition shared their experiences of delayed diagnosis and inadequate support. One received her diagnosis at age 18 with minimal guidance, while the other was initially dismissed by healthcare providers before being diagnosed in 2025. Both described feeling abandoned after receiving their diagnosis, with little ongoing care or monitoring from medical professionals.
The National Institute for Health and Care Excellence published draft guidance recommending annual reviews for women with the condition to monitor symptoms, treatment effectiveness and longer-term health risks. The final guideline is scheduled for publication on 27 January. Medical experts emphasize that the condition extends beyond reproductive health, functioning as a cardiometabolic disorder affecting multiple organ systems throughout a person’s lifetime.
Supporters of the name change argue it better reflects the condition’s complex, whole-body nature and could improve understanding among patients and healthcare providers. However, both women and health professionals stressed that renaming alone is insufficient without systemic improvements to care delivery. They called for comprehensive annual reviews that address the broader health implications of the condition rather than focusing narrowly on weight management or contraceptive options.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI